Uncategorized

Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)

by Business Wire • 2019/09/09 • 0 Comments

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc announces the FDA has granted priority review of the teprotumumab BLA for the treatment of active thyroid eye disease.

← STAAR Surgical Announces EVO ICL Clinical Program for Its 16th Annual Surgical Experts Summit in Paris, France From September 11 – 13, 2019

ProQR’s retinitis pigmentosa treatment receives fast track designation →

Post navigation